Dr. Reddy’s Laboratories and Merck Serono (MS) have entered a partnership to co-develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies (MAbs). The partnership covers development, manufacturing and commercialization of the compounds globally.   Dr. Reddy’s will lead early product development through Phase I; MS will take over manufacturing of the compounds and will lead Phase III development. Both companies will share R&D costs. MS will undertake c...